サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363334

ライフサイエンスBPO市場規模、シェア、動向分析レポート：サービス別、地域別、セグメント予測、2023年～2030年

Life Sciences BPO Market Size, Share & Trends Analysis Report By Services (Pharmaceutical Outsourcing, Medical Devices Outsourcing, Contract Sales And Marketing Outsourcing, Others), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 275 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ライフサイエンスBPO市場規模、シェア、動向分析レポート：サービス別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月27日
発行: Grand View Research
ページ情報: 英文 275 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ライフサイエンスBPO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のライフサイエンスBPO市場規模は2030年までに8,275億米ドルに達し、予測期間のCAGRは9.3％を記録すると予測されています。

医薬品開発、前臨床試験、臨床試験、市販後調査にかかるコストの上昇、特許の崖の上昇、製品パイプラインの増加、規制上の制約などが市場を牽引する主な要因です。製薬業界やバイオテクノロジー業界は、新しい分子、機器、治療法を継続的に導入するため、研究開発部門に多額の投資を行っています。創薬、前臨床試験、臨床試験といった医薬品開発のさまざまな段階では、莫大な資金、技術、人的資源が必要となります。

アウトソーシング・ベンダーは、業界の拡大するニーズに対応するため、製品やサービスの提供を拡大し、長期的な成長と収益性のためにニッチ分野をターゲットとしています。こうした動向を総合すると、予測期間中、ライフサイエンス分野のアウトソーシング市場が拡大すると予想されます。COVID-19の大流行時には、多くのアウトソーシング・プロバイダーがCOVID-19ワクチンや診断薬の需要増に対応するため、既存の製造・研究施設を拡張しました。パンデミック後も、CDMOは将来の医薬品需要を支えるために同様の戦略を実践しています。例えば、アエノバ・グループは2022年4月、1,000万ユーロを投資して高活性医薬品を製造する新施設を開発しました。

市場関係者がこのような戦略を採用することは、市場にとって有益であると予想されます。医薬品や医療機器の製造・開発コストを削減したいという需要が高まっています。製造・研究・マーケティングサービスのアウトソーシングは、製薬・医療機器企業にコストと時間の節約というメリットをもたらします。これは市場にプラスの影響を与えると予想されます。ここ数年、CROとCDMOの合併・買収が増加しています。臨床サービスに対する需要の高まりや、コアコンピタンスへの集中を改善するための専門サービスプロバイダーに対するニーズの高まりは、M&A取引の発生を促進すると予想される要因の一部です。

ライフサイエンスBPO市場のレポートハイライト

  • M&A案件の増加により、CROやCDMOの世界展開が拡大し、エンド・ツー・エンドのサービスを提供する能力が向上しています。この動向の継続は市場に大きな利益をもたらすと予想されます。
  • COVID-19の罹患率は、世界のワクチン接種キャンペーンの拡大により大幅に減少しています。
  • このため、CROやCDMOは現在、負担が大きいがんやその他の疾患の治療薬開発に注力しています。
  • 例えば、2022年4月、LabcorpはXcell Biosciencesと提携し、同社ががん、パーキンソン病、その他の希少疾患を治療するための細胞・遺伝子治療を開発することを支援します。
  • がんやその他の希少疾患の治療における遺伝子治療の高い有効性から、CDMOによるこのようなイニシアチブは市場に利益をもたらす可能性が高いです。
  • 医療機器分野は、医療機器設計に関連する複雑さにより、2023年から2030年にかけて最も速いCAGRを記録すると予想されます。
  • 世界的に医療機器承認のための規制枠組みが厳しいことが、医療機器アウトソーシングサービスの需要をさらに高めています。
  • アジア太平洋地域は、費用対効果の高いBPOサービスを提供するCROが多数存在することから、2022年に最大の売上シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ライフサイエンスBPO市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • ライフサイエンスBPO市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 ライフサイエンスBPO：サービス別推定・動向分析

  • ライフサイエンスBPO市場：重要なポイント
  • ライフサイエンスBPO市場：動向と市場シェア分析、2022年および2030年
  • 医薬品のアウトソーシング
    • 受託製造市場
    • 受託研究機関
  • 医療機器のアウトソーシング
    • 受託製造アウトソーシング
    • 受託研究機関
  • 契約販売およびマーケットアウトソーシング
  • その他

第5章 ライフサイエンスBPO市場：地域別推定・動向分析

  • 地域別の見通し
  • 地域別のライフサイエンスBPO市場：重要なポイント
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Atos SE
    • Boehringer Ingelheim International GmbH
    • Catalent, Inc
    • Labcorp Drug Development
    • Genpact
    • ICON plc
    • Infosys Limited
    • IBM
    • Lonza
    • Parexel
    • IQVIA Inc
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 3 North America life sciences BPO market, by region, 2018 - 2030 (USD Billion)
  • Table 4 U.S. life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 5 Canada Life Sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 6 Europe life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 7 Europe life sciences BPO market, by region, 2018 - 2030 (USD Billion)
  • Table 8 Germany life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 9 UK life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 10 France life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 11 Italy life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 12 Spain life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 13 Sweden life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 14 Norway Life Sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 15 Denmark life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 16 Asia Pacific life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 17 Asia Pacific life sciences BPO market, by region, 2018 - 2030 (USD Billion)
  • Table 18 China Life Sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 19 Japan Life Sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 20 India life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 21 Australia life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 22 Thailand Life Sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 23 South Korea life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 24 Latin America life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 25 Latin America life sciences BPO market, by region, 2018 - 2030 (USD Billion)
  • Table 26 Brazil life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 27 Mexico Life Sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 28 Argentina life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 29 Middle East and Africa life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 30 Middle East and Africa life sciences BPO market, by region, 2018 - 2030 (USD Billion)
  • Table 31 South Africa life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 32 Saudi Arabia Life Sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 33 UAE life sciences BPO market, by services, 2018 - 2030 (USD Billion)
  • Table 34 Kuwait Life Sciences BPO market, by services, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Microneedle drug delivery systems: Market outlook
  • Fig. 9 Microneedle drug delivery systems: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Life sciences BPO market driver impact
  • Fig. 15 Life sciences BPO market restraint impact
  • Fig. 16 Life sciences BPO market strategic initiatives analysis
  • Fig. 17 Life sciences BPO market: Services movement analysis
  • Fig. 18 Life sciences BPO market: Services outlook and key takeaways
  • Fig. 19 Pharmaceutical outsourcing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 API market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Finished dose form market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 23 Packaging market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 24 Contract research organizations market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Drug discovery market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 Preclinical studies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 27 Clinical trial studies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 28 Regulatory services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Medical devices outsourcing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Electronic manufacturing services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Finished goods market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 Raw materials/components market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 Contract research organizations manufacturing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Regulatory consulting services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Product design and development services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Product testing services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Product implementation services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Product upgrade services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Product maintenance services market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 42 Contract sales & market outsourcing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Global life sciences BPO market: Regional movement analysis
  • Fig. 45 Global life sciences BPO market: Regional outlook and key takeaways
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Europe market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 France market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 57 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 59 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 60 China market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 61 India market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 62 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 63 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 64 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 65 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 66 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 67 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 69 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 70 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 72 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 73 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)
目次
Product Code: 978-1-68038-959-3

Life Sciences BPO Market Growth & Trends:

The global life sciences BPO market size is expected to reach USD 827.5 billion by 2030, registering a CAGR of 9.3% over the forecast years, according to a new report by Grand View Research, Inc.. The rising costs of drug development; pre-clinical and clinical trials; and post-marketing surveillance; a rise in the patent cliff; a growing product pipeline; and regulatory constraints are some of the major factors driving the market. The pharmaceutical and biotech industries invest heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of drug development, such as drug discovery, pre-clinical studies, and clinical trials, require huge financial, technological, and human resources.

To cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth and profitability. Altogether, these trends are expected to boost the life sciences outsourcing market over the forecast period. During the COVID-19 pandemic, a significant number of outsourcing providers expanded their existing manufacturing and research facilities to meet the growing demand for COVID-19 vaccines and diagnostics. Even post-pandemic, CDMOs are practicing similar strategies to support the future demand for pharmaceuticals. For instance, in April 2022, Aenova Group developed a new facility for manufacturing highly potent drugs with an investment of EUR 10 million.

The adoption of such strategies by the market players is expected to be profitable for the market. There has been a rising demand to reduce the cost of manufacturing and development of drugs and medical devices. Outsourcing manufacturing, research, and marketing services provide pharmaceutical and medical device companies with cost- and time-saving benefits. This is expected to have a positive impact on the market. Over the years, mergers and acquisition deals between CROs and CDMOs have increased. The rising demand for clinical services and the growing need for specialized service providers to improve the focus on their core competencies are some of the factors that are expected to drive the incidence of M&A deals.

Life Sciences BPOMarket Report Highlights:

  • The increasing number of M&A transactions has broadened the global reach and improved the capabilities of CROs and CDMOs to provide end-to-end services; a continuation of this trend is expected to benefit the market significantly
  • COVID-19 incidence has decreased significantly as a result of a growing global vaccination campaign
  • Owing to this, the CRO and CDMO are now refocusing on developing drugs for oncology and other diseases owing to their high burden
  • For instance, in April 2022, Labcorp collaborated with Xcell Biosciences to support the company in developing cell and gene therapies for treating cancer, Parkinson's, and other rare diseases
  • Such initiatives by the CDMOs are likely to profit the market owing to the high effectiveness of gene therapy in treating cancer and other rare diseases
  • The medical device segment is expected to register the fastest CAGR from 2023 to 2030 due to the complexities associated with medical device designing
  • The strict regulatory framework for medical device approval globally has further contributed to the demand for medical device outsourcing services
  • Asia Pacific held the largest revenue share in 2022 due to the presence of a significant number of CROs providing cost-effective BPO services

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Services
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Services outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Life Sciences BPO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Life Sciences BPO Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Life Sciences BPO: Service Estimates & Trend Analysis

  • 4.1. Life Sciences BPO Market: Key Takeaways
  • 4.2. Life Sciences BPO Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Pharmaceutical Outsourcing
    • 4.3.1. Pharmaceutical outsourcing market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2. Contract manufacturing market
      • 4.3.2.1. Contract manufacturing market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.2. API
      • 4.3.2.2.1. API estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.3. Finished dose form
      • 4.3.2.3.1. Finished dose form estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.4. Packaging
      • 4.3.2.4.1. Packaging estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3. Contract research organizations
      • 4.3.3.1. Contract research Organizations estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.3.2. Drug discovery
      • 4.3.3.2.1. Drug discovery estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.3.3. Preclinical studies
      • 4.3.3.3.1. Preclinical studies estimate and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.3.4. Clinical Trial Studies
      • 4.3.3.4.1. Clinical trial studies estimate and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.3.5. Regulatory services
      • 4.3.3.5.1. Regulatory services estimate and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.3.6. Pharmacovigilance
      • 4.3.3.6.1. Pharmacovigilance estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.4. Medical Devices Outsourcing
    • 4.4.1. Medical devices outsourcing market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.2. Contract manufacturing outsourcing
      • 4.4.2.1. Contract manufacturing outsourcing estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.2.2. Electronic manufacturing services
      • 4.4.2.2.1. Electronic manufacturing services estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.2.3. Finished goods
      • 4.4.2.3.1. Finished goods estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.2.4. Raw materials/components
      • 4.4.2.4.1. Raw materials/components estimate and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3. Contract research organizations
      • 4.4.3.1. Contract research Organizations estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.3.2. Regulatory consulting services
      • 4.4.3.2.1. Regulatory consulting services estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.3.3. Product design and development services
      • 4.4.3.3.1. Product design and development services estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.3.4. Product testing services
      • 4.4.3.4.1. Product testing services estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.3.5. Product implementation services
      • 4.4.3.5.1. Product implementation services estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.3.6. Product upgrade services
      • 4.4.3.6.1. Product upgrade services estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.4.3.7. Product maintenance services
      • 4.4.3.7.1. Product maintenance services estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.5. Contract Sales & Market Outsourcing
    • 4.5.1. Contract sales & market outsourcing market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Life Sciences BPO Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Life Sciences BPO Market by Region: Key Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Atos SE
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Boehringer Ingelheim International GmbH
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Catalent, Inc
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Labcorp Drug Development
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Genpact
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. ICON plc
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Infosys Limited
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. IBM
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. Lonza
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Parexel
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. IQVIA Inc
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives